株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

血友病の世界市場:成長、動向、および予測(2019年~2024年)

Hemophilia Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 911950
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
血友病の世界市場:成長、動向、および予測(2019年~2024年) Hemophilia Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年09月01日 ページ情報: 英文 115 Pages
概要

世界の血友病市場は、2019年から2024年の間に5.9%のCAGR成長する見通しです。市場の成長を促進する主な要因には、血友病の有病率の増加、前向きな政府の取り組み、研究開発および新製品の開発の増加などが挙げられます。

当レポートは世界の血友病市場について調査しており、市場機会や動向、成長および阻害要因、疾患タイプ・治療・製品タイプ・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 疾患のタイプ別
    • 血友病A
    • 血友病B
    • その他
  • 治療法別
    • 補充療法
    • 遺伝子治療
    • その他
  • 製品タイプ別
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Bayer AG
    • BioMarin Pharmaceutical, Inc.
    • CSL Behring
    • Kedrion S.p.A
    • Novo Nordisk
    • Pfizer, Inc.
    • Roche (Chugai Pharmaceutical Co.)
    • Sanofi (Genzyme Corporation)
    • 武田薬品工業株式会社(Shire Plc.)

第7章 市場機会および今後の動向

目次
Product Code: 66766

Market Overview

Hemophilia market is expected to witness a CAGR of 5.9% during the forecast period. Certain factors that are driving the market growth include growing prevalence of hemophilia, favorable government initiatives, and rising R&D and new product development.

Hemophilia, a genetic bleeding disorder that prevents the blood from clotting normally affects 1 in 5,000 male births. About 400 babies are born with hemophilia each year in the United States. As per the World Federation of Hemophilia, 184,723 people were affected with Hemophilia in 2016, along with 39,495 people with other bleeding disorders. Similarly according to the World Health Organization (WHO), owing to the sex-linkage of the disorder, there is a bigger prominence in males than in females. About 1/3rd of new diagnoses are where there is no earlier family history. It appears worldwide and is observed across all racial groups. About 6,000 people are suffering from hemophilia in the United Kingdom (as in 2018). There are approximately 5400 people in the UK with hemophilia A and about 1100 with hemophilia B. Hence the high prevalence of the disease is acting as one of the factors fueling the market growth all across the globe.

Scope of the Report

Hemophilia is a genetic bleeding disorder that prevents the blood from clotting normally. The primary symptom is uncontrolled, often spontaneous bleeding in different areas of the body. The amount of bleeding depends on the severity of hemophilia.

Key Market Trends

Hemophilia A is Expected to Hold Significant Market Share in the Disease Type Segment

According to the National Hemophilia Foundation (NHF), the United States, the two major forms of hemophilia occur much more frequently in males than in females. Hemophilia A is the most prevalent type of condition with the incidence rate of 1 in 4,000 to 1 in 5,000 males worldwide who are born with this disorder. Whereas Hemophilia B occurs in approximately 1 in 20,000 newborn males all across the globe. The key medication to treat hemophilia A is concentrated FVIII product, also called clotting factor or simply factor. Recombinant factor products, that are developed in a laboratory through the use of DNA technology, impede the use of human-derived pools of donor-sourced plasma. And while plasma-derived FVIII products are still available, approximately 75% of the hemophilia-affected community takes a recombinant FVIII product (as per the NHF).

North America Dominates the Market and Expected to do Same in the Forecast Period

NHF is an organization that has been awarding grants and fellowships in order to support innovative research intended for finding better treatments and cures for several bleeding disorders. Such researches have led to vital insights into improved factor replacement therapies, along with more accurate hemophilia diagnostic methods and therefore definitely a greater understanding of the genetic basis of the disease. Through the efforts and guidance of NHF's Medical and Scientific Advisory Council (MASAC), an internationally distinguished group of expert scientists, physicians as well as other treatment specialists, NHF has been engaged since long in advancing the standard of clinical care and issuing treatment recommendations for hemophilia. Moreover, NHF states that the number of people with hemophilia in the United States is estimated to be about 20,000 individuals in 2019. Hence, owing to the rising prevalence of the disease along with the growing initiatives by several organizations is driving the market growth in the region.

Competitive Landscape

The Hemophilia market is highly competitive and consists of a few major players. Companies like Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), Takeda Pharmaceutical (Shire Plc.)., among others, hold the substantial market share in the Hemophilia market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Hemophilia
    • 4.2.2 Favorable Government Initiatives
    • 4.2.3 Rising R&D and New Product Development
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Lack of Awareness Regarding Advanced Technologies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Disease Type
    • 5.1.1 Hemophilia A
    • 5.1.2 Hemophilia B
    • 5.1.3 Others
  • 5.2 Therapy
    • 5.2.1 Replacement Therapy
    • 5.2.2 Gene Therapy
    • 5.2.3 Others (Immune Tolerance Induction Therapy etc.)
  • 5.3 Product Type
    • 5.3.1 Recombinant Coagulation Factor Concentrates
    • 5.3.2 Plasma-derived Coagulation Factor Concentrates
    • 5.3.3 Others (Desmopressin etc.)
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 BioMarin Pharmaceutical, Inc.
    • 6.1.3 CSL Behring
    • 6.1.4 Kedrion S.p.A
    • 6.1.5 Novo Nordisk
    • 6.1.6 Pfizer, Inc.
    • 6.1.7 Roche (Chugai Pharmaceutical Co.)
    • 6.1.8 Sanofi (Genzyme Corporation)
    • 6.1.9 Takeda Pharmaceutical (Shire Plc.)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top